No insider purchase over the last 90 days. The latest, by 董明, was filed 17 May 2022.
Yunnan Baiyao Group Co.,Ltd: what insiders have been doing
We have very little insider data for Yunnan Baiyao Group Co.,Ltd so far: the most recent filing dates from 17 May 2022. With so few records, no pattern can be drawn yet. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.
Since the insiders bought
- -0.7%Entry CN¥57.50 · Close at T+365 CN¥57.11
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Yunnan Baiyao Group Co.,Ltd Strong Buy (bullish), based on 10 analysts. Average price target: CN¥67.86.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 13,280 shares100.0% of flowA股XSHESZSE:173000005533351170Canonical exit: 15 Aug 2022 (T+90)
1 of 1 declaration
About Yunnan Baiyao Group Co.,Ltd
云南白药 is a Chinese company specializing in pharmaceutical and health products, known for its traditional medicines and innovative treatments. It is listed on the XSHE stock market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
